Table 1. Survival and extensive cGVHD... | American Society of Hematology

Table 1.

Survival and extensive cGVHD incidence among children undergoing myeloablative HLA-matched sibling hematopoietic stem cell transplantation

Reference	Survival	N	2 y (%)	4 to 5 y (%)	6 to 8 y (%)	cGVHD (%)
31		24				4
	OS		100	100	100
	DFS		96	96	96
30		38				0
	OS		97.4	97.4	97.4
	DFS		97.4	97.4	97.4
54		40				5
	OS		91	91	NR
	DFS		91	91	NR
36		130				5*
	OS		NR	NR	95*
	DFS		NR	NR	92
55		25				0
	OS		96	96	NR
	DFS		96	96	NR
49		57				8
	OS		93	93	93
	DFS		85	85	85
56		10				10
	OS		90	90	NR
	DFS		90	90	NR
57		67				5
	OS		97	97	NR
	DFS		85	85	NR
51		44				2.4
	OS		NR	100	NR
	DFS		NR	95.6	NR
58		50				6
	OS		98	96	NR
	DFS		88	86.1	NR
Total		485				5
	OS†		95	96	95
	DFS†		89	90	91

Reference	Survival	N	2 y (%)	4 to 5 y (%)	6 to 8 y (%)	cGVHD (%)
31		24				4
	OS		100	100	100
	DFS		96	96	96
30		38				0
	OS		97.4	97.4	97.4
	DFS		97.4	97.4	97.4
54		40				5
	OS		91	91	NR
	DFS		91	91	NR
36		130				5*
	OS		NR	NR	95*
	DFS		NR	NR	92
55		25				0
	OS		96	96	NR
	DFS		96	96	NR
49		57				8
	OS		93	93	93
	DFS		85	85	85
56		10				10
	OS		90	90	NR
	DFS		90	90	NR
57		67				5
	OS		97	97	NR
	DFS		85	85	NR
51		44				2.4
	OS		NR	100	NR
	DFS		NR	95.6	NR
58		50				6
	OS		98	96	NR
	DFS		88	86.1	NR
Total		485				5
	OS†		95	96	95
	DFS†		89	90	91

Incidence not differentiated between patients with sickle cell anemia and thalassemia.

†

Percentages are calculated based on the total number of patients reported at that time period because some manuscripts did not report survival at every interval listed in the table.

NR, not reported.

View Large

This Feature Is Available To Subscribers Only